The Indian pharmaceutical industry will weather the current headwinds of slowdown in exports caused by regulatory scrutiny and intensifying competition, by monetising opportunities in complex products in the regulated markets, and because of resilient domestic demand, according to credit rating ...
Read more: Complex generics, domestic demand to help pharma weather regulated market de-growth